[Dibekacin in bronchopulmonary infectious pathology].
Thirty six patients in an intensive care unit with a bacterial bronchopulmonary infection were treated with intraparenteral dibekacin at a dose of 3 mg/kg/day. Mean age of the patients was 55 years and the mean duration of treatment 14 days. Biological material was obtained by fibro-aspiration or pleural tap. One or more organisms were identified in 36 cases. These were essentially staphylococci and Gram negative bacilli sensitive to dibekacin. Results showed a favourable course in 26 cases and a clinical improvement in 10. Clinical and biological tolerance was good. No clinical manifestations of cochleo-vestibular toxicity were seen.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D003982:Dibekacin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D007612:Kanamycin / Q000031:analogs & derivatives*; D008171:Lung Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D003982:Dibekacin; D007612:Kanamycin
La dibékacine en pathologie infectieuse bronchopulmonaire.